A chondroprotective effect of aceclofenac in the osteoarthritis Commentary
Article Sidebar
Published:
Mar 31, 2013
Main Article Content
Abstract
None
Article Details
How to Cite
Rupiński , R. (2013). A chondroprotective effect of aceclofenac in the osteoarthritis. Medycyna Faktow (J EBM), 6(1(18), 81-83. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2432
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Legrand E.: Aceclofenac in the management of inflammatory pain. Expert Opin. Pharmacother. 2004; 5(6): 1347-1357.
2. Klimiuk P.A., Kuryliszyn-Moskal A.: Choroba zwyrodnieniowa stawów. W: Reumatologia. Puszczewicz M. (red.). Medical Tribune Polska, Warszawa 2011: 271-290.
3. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis – a study of the mechanism of action of aceclofenac. Clin. Drug. Invest. 1997; 14: 353-362.
4. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
5. Szałek E., Grześkowiak E.: Aceklofenak – NLPZ preferencyjnie hamujący cyklooksygenazę 2 o działaniu chondroprotekcyjnym. Geriatria 2012; 6: 158-165.
6. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28(12): 2692-2699.
2. Klimiuk P.A., Kuryliszyn-Moskal A.: Choroba zwyrodnieniowa stawów. W: Reumatologia. Puszczewicz M. (red.). Medical Tribune Polska, Warszawa 2011: 271-290.
3. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis – a study of the mechanism of action of aceclofenac. Clin. Drug. Invest. 1997; 14: 353-362.
4. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
5. Szałek E., Grześkowiak E.: Aceklofenak – NLPZ preferencyjnie hamujący cyklooksygenazę 2 o działaniu chondroprotekcyjnym. Geriatria 2012; 6: 158-165.
6. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28(12): 2692-2699.